Potential use of γδ T cell-based vaccines in cancer immunotherapy

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Khan, Mohd Wajid A ^a   Eberl, Matthias ^a   Moser, Bernhard ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antigen presenting cells; Cancer; Immunotherapy; Vaccine; T cells

Indexed keywords

APC PROTEIN; B7 ANTIGEN; CD11B ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR5; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ADHESION; CELL KILLING; CELL PROLIFERATION; CROSS PRESENTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; SHORT SURVEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

EID: 84918767369     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00512     Document Type: Short Survey

References (47)

1. Moser B, Eberl M. gammadelta T cells: novel initiators of adaptive immunity. Immunol Rev (2007) 215:89-102. doi: 10.1111/j.1600-065X.2006.00472.x
2. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev (2007) 215:59-76. doi:10.1111/j.1600-065X.2006.00479.x
3. Riganti C, Massaia M, Davey MS, Eberl M. Human gammadelta T-cell responses in infection and immunotherapy: common mechanisms, common mediators? Eur J Immunol (2012) 42:1668-76. doi:10.1002/eji.201242492
4. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol (2001) 2:123-8. doi:10.1038/84219
5. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 9:970-80. doi:10.1038/ni.f.213
6. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med (2000) 192:1545-52. doi:10.1084/jem.192.11.1545
7. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med (2000) 192:1553-62. doi:10.1084/jem.192.11.1553
8. Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB, et al. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. Blood (2003) 102:3693-701. doi:10.1182/blood-2003-04-1016
9. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol (2000) 18:593-620. doi:10.1146/annurev.immunol.18.1.593
10. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, et al. CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol (2006) 177:5290-5. doi:10.4049/jimmunol.177.8.5290
11. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human gammadelta T cells to provide B-cell help. Eur J Immunol (2012) 42:110-9. doi:10.1002/eji.201142017
12. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940
13. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science (2005) 309:264-8. doi:10.1126/science.1110267
14. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature (1988) 334:530-2. doi:10.1038/334530a0
15. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev (2005) 207:145-57. doi:10.1111/j.0105-2896.2005.00316.x
16. Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, et al. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 106:2307-12. doi:10.1073/pnas.0810059106
17. Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci U S A (2010) 107:8730-5. doi:10.1073/pnas.1002769107
18. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol (2012) 188:1708-16. doi:10.4049/jimmunol.1102654
19. Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol (2009) 183:5622-9. doi:10.4049/jimmunol.0901772
20. Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, et al. Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. J Immunother (2009) 32:310-21. doi:10.1097/CJI.0b013e31819b7c30
21. Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, et al. Activated human gammadelta T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunol Immunother (2012) 61:385-96. doi:10.1007/s00262-011-1111-6
22. Holtmeier W, Kabelitz D. gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy (2005) 86:151-83. doi:10.1159/000086659
23. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol (2013) 13:88-100. doi:10.1038/nri3384
24. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother (2007) 56:469-76. doi:10.1007/s00262-006-0199-6
25. Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas delaPintièreC, Daniel P, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother (2008) 57:531-9. doi:10.1007/s00262-007-0391-3
26. Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol (2007) 139:206-16. doi:10.1111/j.1365-2141.2007.06754.x
27. Salot S, Laplace C, Saïagh S, Bercegeay S, Tenaud I, Cassidanius A, et al. Large scale expansion of gamma 9 delta 2 T lymphocytes: innacell gamma delta cell therapy product. J Immunol Methods (2007) 326:63-75. doi:10.1016/j.jim.2007.07.010
28. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, et al. Phase-I study of innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2008) 57:1599-609. doi:10.1007/s00262-008-0491-8
29. Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy (2008) 10:842-56. doi:10.1080/14653240802419328
30. Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology (2009) 126:256-67. doi:10.1111/j.1365-2567.2008.02894.x
31. Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, et al. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother (2010) 59:1611-9. doi:10.1007/s00262-010-0887-0
32. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother (2011) 60:1075-84. doi:10.1007/s00262-011-1021-7
33. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer (2011) 105:778-86. doi:10.1038/bjc.2011.293
34. Yamasaki A, Onishi H, Morisaki T, Katano M. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed gammadelta T-cells isolated from patients with advanced cancer. Anticancer Res (2011) 31:2419-24.
35. Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, et al. Zoledronic acid-induced expansion of gammadelta T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol Immunother (2013) 62:677-87. doi:10.1007/s00262-012-1368-4
36. Khan MW, Curbishley SM, Chen HC, Thomas AD, Pircher H, Mavilio D, et al. Expanded human blood-derived gammadeltaT cells display potent antigen-presentation functions. Front Immunol (2014) 5:344. doi:10.3389/fimmu.2014.00344
37. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2009) 144:245-50. doi:10.1111/j.1365-2141.2008.07435.x
38. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102:200-6. doi:10.1182/blood-2002-12-3665
39. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 102:2310-1. doi:10.1182/blood-2003-05-1655
40. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 67:7450-7. doi:10.1158/0008-5472.CAN-07-0199
41. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 161:290-7. doi:10.1111/j.1365-2249.2010.04167.x
42. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. J Transl Med (2014) 12:45. doi:10.1186/1479-5876-12-45
43. Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res (2010) 18:493-501. doi:10.3727/096504010X12671222663638
44. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab (2010) 95:4380-7. doi:10.1210/jc.2010-0597
45. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 12:307-13. doi:10.1038/nrc3246
46. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 19:5283-91. doi:10.1158/1078-0432.CCR-13-2151
47. Boon T, Coulie PG, Van den Eynde BJ, van der BP. Human T cell responses against melanoma. Annu Rev Immunol (2006) 24:175-208. doi:10.1146/annurev.immunol.24.021605.090733